|
|
|
|
|
|
|
Grifols S.A. (GRFS)
|
|
20.66 -0.1 (-0.48%)
|
04-23 16:00
|
|
Open:
|
20.83
|
Pre. Close:
|
20.76
|
|
High:
|
20.83
|
Low:
|
20.59
|
|
Volume:
|
599,558
|
Market Cap:
|
17649M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
20.856 - 20.958
|
20.958 - 21.058
|
|
Low:
|
20.287 - 20.416
|
20.416 - 20.543
|
|
Close:
|
20.422 - 20.626
|
20.626 - 20.827
|
|
|
|
Technical analysis (as of: 2018-04-23 4:29:53 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a SELL today, downgraded from higher rating. This stock seems to be ready for a new bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.
|
|
Target:
|
Six months: 24.47 One year: 25.10
|
|
Support:
|
Support1: 20.07 Support2: 16.70
|
|
Resistance:
|
Resistance1:
20.95 Resistance2: 21.49
|
|
Pivot:
|
20.75 
|
|
Moving Averages:
|
MA(5): 20.87 MA(20): 20.75
MA(100): 22.31 MA(250): 21.74
|
|
MACD:
|
MACD(12,26):
-0.15 Signal(12,26,9): -0.21
|
|
%K %D:
|
%K(14,3): 46.84 %D(3): 54.58
|
|
RSI:
|
RSI(14): 44.45
|
|
52-Week:
|
High: 25.18
Low: 19.92 Change(%): 0.2
|
|
Average Vol(K):
|
3-Month: 63276
10-Days 72482
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.GRFS has closed above bottom band by 40.8%. Bollinger Bands are 51.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to GRFS's normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
|
|
|
Headline News
|
|
2018-04-16T11:21:00-04:00
Grifols donates over 25 million international units of blood clotting factor in 2017
2018-04-10T14:14:33-04:00
Now Could Be The Right Time To Buy Grifols With Worries Over Trade With China
2018-04-06T10:40:00-04:00
Grifols 2017 Annual Report on Form 20-F filed with the SEC on April 6, 2018
2018-03-12T08:00:00-04:00
3 Things In Biotech, March 11: Aradigm Retries, Pfizer Glides, VBL Crashes
2018-03-06T07:36:21-05:00
ADMA Biologics: Almost Ready To Run Between The Toes Of Giants
2018-03-05T09:00:00-05:00
Grifols Announces New Agreement with Henry Schein to Distribute Normal Saline Solution in the U.S.
2018-02-28T10:05:00-05:00
Grifols Shines Light on Rare Disease with Launch of Educational Campaign "Look Into Genetic COPD"
2018-02-06T09:45:00-05:00
Grifols HyperRAB® (rabies immune globulin [human]) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection
|
|
|
Financial Analysis
|
|
Growth
|
NA
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
NA
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
NA
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
NA
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
